Home | Cardiovascular Business

Abbott described the update as "critically important," and the American College of Cardiology expressed relief that some proposed changes did not actually end up happening.

Read more about CMS expands Medicare coverage for TMVR, now known as TEER, to include patients with functional MR

The authors examined data from more than 1.2 million patients, tracking individuals who had previously been hospitalized for heart failure and then returned later due to COVID-19.

Read more about 24% of heart failure patients hospitalized with COVID-19 die

Hypertension patients measured their blood pressure less frequently during the early months of the COVID-19 pandemic, according to new research published in Hypertension. In addition, when those patients did measure their blood pressure, the readings were less healthy than they had been before the pandemic.

Researchers compared patient outcomes from 2019 with data from the pandemic’s first four months, sharing their findings in the American Journal of Cardiology.

Read more about TAVR in the time of COVID-19: Providers quickly adapted, delivering ‘excellent’ outcomes

Prior to popular belief, sex may not necessarily be an independent risk factor for stroke mortality, according to the analysis.

Read more about What new research tells us about stroke mortality among men and women

Driven by its strategic goal to advance equity in the U.S. healthcare innovation sector, the American Medical Association (AMA) recently announced an initiative that supports leading industry stakeholders in committing to equitable health innovation opportunities targeted to improving health outcomes in historically marginalized communities. #Healthdisparities

Patients are typically told to put anticoagulation therapy on hold two to four days before they undergo TAVR. This study’s authors aimed to see if this was truly necessary.

Read more about No reason to quit: TAVR patients can continue anticoagulation therapy throughout procedure

New findings out of the University of Missouri suggests that the long-lasting impact of COVID-19 may not be quite as substantial as some researchers originally believed. The study’s authors evaluated nearly 50 different symptoms to see if they were more common up to one year after a person has been infected with COVID-19. They found, however, that this was true of just seven symptoms: heart palpitations, chest pain, shortness of breath, joint pain, hair loss, fatigue and obesity. #COVID19 #longCOVID

The research included data from more than 47,000 hospitalized COVID-19 patients.

Read more about When hospitalized COVID-19 patients head home, the cardiovascular challenges continue

The authors found a link between six months of empagliflozin and a reduction in extracellular volume, sharing their findings in JACC: Cardiovascular Imaging.

Read more about Empagliflozin provides additional benefits to patients with type 2 diabetes and CAD

Read more about Expert Panel: 2020 Valvular Heart Disease Guidelines: Recommendations on Treatment, TAVR and Decision-making

Summary

Just-released valvular heart disease guidelines favor transcatheter interventions for the right patient and more shared decision-making among heart teams, physicians and severe aortic stenosis patients with an eye toward types of valves and approaches, and lifetime benefits and risks.

For patients undergoing PCI, subclinical hypothyroidism was associated with higher short-term and long-term mortality.

Read more about Why STEMI patients undergoing PCI should be tested for subclinical hypothyroidism

Researchers were able to predict, with considerable accuracy, each patient's 5- and 10-year risk of heart failure.

Read more about How to predict heart failure among patients with diabetes, prediabetes

Design by Adaptive Theme